- Home
- OCGN
OCGN
Ocugen Inc.
as 11-08-2024 11:37am EST
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | MALVERN |
| Market Cap: | 338.2M | IPO Year: | N/A |
| Target Price: | $5.33 | AVG Volume (30 days): | 3.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.35 - $2.10 | Next Earning Date: | 11-08-2024 |
| Revenue: | $7,263,000 | Revenue Growth: | 112.62% |
| Revenue Growth (this year): | -53.48% | Revenue Growth (next year): | N/A |
Latest Ocugen Inc. News
OCGN Breaking Stock News: Dive into OCGN Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 hours ago
Ocugen Provides Business Update with Third Quarter 2024 Financial Results
GlobeNewswire
a day ago
Ocugen Secures $30 Million in Debt Funding
Simply Wall St.
8 days ago
Those who invested in Ocugen (NASDAQ:OCGN) a year ago are up 163%
GlobeNewswire
11 days ago
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024
MT Newswires
17 days ago
Ocugen Receives Approval to Begin Dosing in Phase 2 Trial of CU410ST to Treat Genetic Eye Disease
GlobeNewswire
17 days ago
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
GlobeNewswire
22 days ago
Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
GuruFocus.com
23 days ago
State Street Corp's Strategic Acquisition of Shares in Ocugen Inc
Compare OCGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCGN Ocugen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.